Candel Therapeutics reports phase 3 prostate cancer biomarker data showing sustained immune remodeling after aglatimagene treatment

Bitget2026/09/30 12:08

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Candel Therapeutics disclosed new biomarker data from its completed phase 3 aglatimagene besadenovec trial in localized prostate cancer.
Results were presented at ASTRO 2026 on Sept. 29, 2026, following earlier phase 3 clinical outcome disclosures.
Analysis indicated treatment drove sustained immune remodeling in tumor tissue more than two years after therapy versus radiotherapy alone.
Findings supported earlier evidence of improved biopsy outcomes, underpinning the product’s proposed value proposition in localized prostate cancer.
Management positioned the data package as supportive of its planned Biologics License Application submission.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Candel Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609300805PRIMZONEFULLFEED9836237) on September 30, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Candel Therapeutics reports phase 3 prostate cancer biomarker data showing sustained immune remodeling after aglatimagene treatment

You may also like

Crypto prices